Markets:

Overview

News

Currencies

International

Treasuries

HEALTHCARE (NY:XLV)

154.74 +0.92 (+0.60%)

Official Closing Price Updated: 8:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about HEALTHCARE

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

42 43 Next >

Financials, Health Care Sectors Leading US Stocks Higher In 2025 ↗

February 07, 2025

Genius remains a bull market so far in 2025. All the main sectors in the US equities market are posting year-to-date gains, led by financials and health care, based on a set of ETFs.

Via Talk Markets

Topics ETFs

Regeneron Stock Down 30% Over Past 6 Months: Leerink Sees Buying Opportunity, Retail's On The Same Page ↗

February 06, 2025

The analyst sees 2025 as a challenging year due to Eylea headwinds but expects growth to accelerate in 2026, driven by strong eczema treatment sales from the company’s Dupixent drug.

Via Stocktwits

Bristol-Myers Squibb Stock Slides On Weak 2025 Outlook, Retail Steps In To Buy The Dip ↗

February 06, 2025

The company announced plans to generate $2 billion in annual cost savings by the end of 2027.

Via Stocktwits

Leading And Lagging Sectors For February 6, 2025 ↗

February 06, 2025

Via Benzinga

Eli Lilly's Blockbuster Obesity Drugs Miss Sales Estimates Again, But Investors Cheer Q4 Earnings Beat ↗

February 06, 2025

Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments.

Via Stocktwits

Communications Have More To Say ↗

February 03, 2025

Last week was certainly memorable, and it looks like this week is off to a similar start.

Via Talk Markets

Topics Stocks / Equities

Leading And Lagging Sectors For February 5, 2025 ↗

February 05, 2025

Via Benzinga

Merck Retail Traders See Buying Opportunity As Stock Dives Toward Worst Day in 17 Years On Weak Guidance ↗

February 04, 2025

Gardasil, its HPV vaccine, posted a 17% decline in sales to $1.55 billion, primarily due to lower demand in China.

Via Stocktwits

Pfizer's Retail Traders Cheer Better-Than-Expected Q4 Even As Stock Dips: ‘Another Beat And Still Crazy Cheap' ↗

February 04, 2025

Under its restructuring program, Pfizer said it remains on track to deliver $4.5 billion in cost savings by the end of 2025.

Via Stocktwits

Leading And Lagging Sectors For February 4, 2025 ↗

February 04, 2025

Via Benzinga

Can Biotech Stocks Survive The Precarious Macro? ↗

February 03, 2025

We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows.

Via Talk Markets

Topics Stocks / Equities World Trade

Leading And Lagging Sectors For February 3, 2025 ↗

February 03, 2025

Via Benzinga

Trump's 25% Tariffs Could Slaughter Canada, Mexico Economies, Hit US Auto Industry, Analysts Warn ↗

January 31, 2025

Trade war between US, Canada, and Mexico could cause severe economic damage, raise prices, and disrupt supply chains in key industries.

Via Benzinga

Topics Government World Trade

AbbVie Stock Nears 3-Month High on Q4 Beat As Immunology Growth Eases Humira Slump: Retail Mood Brightens ↗

January 31, 2025

The company raised its long-term sales outlook for Skyrizi and Rinvoq, now expecting combined revenue of about $24 billion in 2025.

Via Stocktwits

Leading And Lagging Sectors For January 31, 2025 ↗

January 31, 2025

Via Benzinga

How We Can Trade On GDP ↗

January 30, 2025

What we got today, of course, was advance GPD, which is the earliest measure and also the most likely to provoke a reaction in stocks.

Via Talk Markets

Topics Commodities Futures Stocks / Equities

Leading And Lagging Sectors For January 30, 2025 ↗

January 30, 2025

Via Benzinga

Leading And Lagging Sectors For January 29, 2025 ↗

January 29, 2025

Via Benzinga

Does China AI Threaten US Tech Dominance? ↗

January 28, 2025

Anxiety about the competitive threat from Chinese artificial intelligence lab DeepSeek triggered a sharp selloff in US equities on Monday, with the worst of the decline centered in tech.

Via Talk Markets

Topics Artificial Intelligence ETFs

Leading And Lagging Sectors For January 28, 2025 ↗

January 28, 2025

Via Benzinga

Biotech And Healthcare Stocks Poised For Gains Ahead ↗

January 27, 2025

The XLV bounced off the bottom this month up 4% to the $144 level led by biopharma and medtech.

Via Talk Markets

Topics ETFs Stocks / Equities

Leading And Lagging Sectors For January 27, 2025 ↗

January 27, 2025

Via Benzinga

Moderna Retains Retail Support With European COVID-19 Vaccine Tender Win, Stock Hits 2-Week High ↗

January 24, 2025

The agreement, which spans up to four years, allows 17 participating countries access to Moderna’s vaccine in various formats.

Via Stocktwits

Leading And Lagging Sectors For January 24, 2025 ↗

January 24, 2025

Via Benzinga

Elevance Health Stock Rises On Upbeat Q4 Revenue, Dividend Boost: Retail's Over The Moon ↗

January 23, 2025

The firm’s medical-loss ratio (MLR) rose to 92.4% due to Medicaid-related costs but was better than expected.

Via Stocktwits

Leading And Lagging Sectors For January 23, 2025 ↗

January 23, 2025

Via Benzinga

J&J Stock Dips As 2025 Sales Guidance Misses Estimate, But Retail Mood Resilient ↗

January 22, 2025

During the earnings call, J&J highlighted several growth drivers, including its positioning for 5%-7% annual growth through 2030 and plans to increase its dividend annually.

Via Stocktwits

Topics Earnings

Leading And Lagging Sectors For January 22, 2025 ↗

January 22, 2025

Via Benzinga

Small Caps Soar, Apple Slips, Treasury Yields Fall On Trump Day 2: What's Driving Markets Tuesday? ↗

January 21, 2025

Wall Street saw a strong preference for small and mid-cap equities, with the Russell 2000 index leading the market as investors bet on more domestic-friendly policies following Donald Trump's...

Via Benzinga

Topics Government

Moderna Stock Jumps On $590M US Award For Bird Flu Vaccine Development, But Retail Doubts Longevity Under Trump ↗

January 21, 2025

In 2023, Moderna initiated a Phase 1/2 study to assess the safety and immunogenicity of its investigational bird flu vaccine, mRNA-1018, in healthy adults aged 18 and older.

Via Stocktwits

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

42 43 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

HEALTHCARE (NY:XLV)

All News about HEALTHCARE

Starting at $3.75/week.

Subscribe Today